Basic Information
LIGNOCAINE INJECTION 2% (Without preservative)
INJECTION
Regulatory Information
SIN05673P
April 8, 1991
Prescription Only
Therapeutic
INTRAVENOUS
August 10, 2023
May 30, 2025
XN01BB02
Company Information
Active Ingredients
Strength: 20 mg/ml
Detailed Information
Contraindications
**4.3 Contraindications** - Allergy or hypersensitivity to local anaesthetics of the amide type or to any excipients. Detection of suspected hypersensitivity by skin testing is of limited value. - Inflammation and/or sepsis at the proposed site of injection and/or in the presence of septicaemia. - Patients with myasthenia gravis, severe shock or impaired cardiac conduction. - Epidural or spinal anaesthesia in patients with - uncorrected hypotension or - coagulation disorders or receiving anticoagulants or - serious diseases of the central nervous system or spinal cord such as meningitis, spinal fluid block, cranial or spinal haemorrhage, tumours, poliomyelitis, syphilis, tuberculosis or metastatic lesions of the spinal cord. - Antiarrhythmic use in patients with - supraventricular arrhythmia or - Stokes-Adams Syndrome or severe degrees of sinoatrial, atrioventricular or intraventricular block unless the patient has an artificial pacemaker. - Lidocaine (lignocaine) suppresses ventricular pacemaker activity and may cause ventricular standstill in such patients. - General contraindications related to epidural anaesthesia, regardless of the local anaesthetic used, should be taken into account.
Indication Information
**4.1 Therapeutic indications** Lidocaine (lignocaine) is indicated for production of local or regional anaesthesia by nerve block, infiltration injection, caudal or other epidural blocks. Treatment or prophylaxis of life-threatening ventricular arrhythmias, including those associated with myocardial infarction, general anaesthesia in patients predisposed to ventricular arrhythmias, digitalis intoxication, or following resuscitation from cardiac arrest.